Jim Cramer - Mad Money Summit Therapeutics SMMT-Q DON'T BUY Jan 31, 2025

Doesn't make money and is a risky spec.

Jim Cramer - Mad Money

Unknown

Unlock Rating

$21.500

Stock price when the opinion was issued

biotechnology pharmaceutical

It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

Get Signals Create your Watchlist

Most Recent Experts

Stockchase Insights

5i Research

Michael Hakes - CFA, MBA

Murray Wealth Group

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Jim Lebenthal

Cerity Partners

Brenda Vingiello, CIO, Sand Hill Global Advisors

Sand Hill Global Advisors

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : hello@stockchase.com.

Jim Cramer - Mad Money Summit Therapeutics SMMT-Q DON'T BUY Jan 31, 2025

Latest Buy Signals

Today's Top Picks

Popular Articles

Latest Sell Signals